Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced ...
16 hrs ago | me-newswire.net
xml encoding="UTF-8"> European Medicines Agency Accepts Regulatory Submission of Type II Variation for ABRAXANE for the Treatment of Advanced Pancreatic Cancer ( BUSINESS WIRE )-- Celgene International Sàrl, a subsidiary of...
Read more...
ABRAXANE Celgene cancer sNDA pancreatic Priority treatment metastatic FDA Review albumin-bound